Metastatic Pancreatic Cancer

Publication Date: August 5, 2020

Key Points

Key Points

  • There will be an estimated 57,600 new cases and 47,050 deaths as a result of pancreatic cancer in the United States in 2020. There were an estimated 460,000 new cases worldwide in 2018.
  • A diagnosis of pancreatic ductal adenocarcinoma is associated with poor prognosis due to early micrometastatic spread.
  • The 5-year survival rate for metastatic pancreatic cancer is approximately 2.9%.
  • This 2020 update of the 2018 recommendations was triggered by:
    • New evidence for PARP inhibitor olaparib as an option for maintenance therapy after first-line treatment and
    • New studies of tissue agnostic agents that target fusions of the neurotrophin tyrosine receptor kinase (NTRK) 1/2/3 genes.

Diagnosis

...iagnos...

...itial Assessm...

...mputerized tomography (CT) scan of the chest, a...

...ine performance status (PS), symptom burden, a...

The goals of care (to include a discussion of an a...

...inary collaboration to formulate trea...

...g for actionable genomic alterations i...

...ient with pancreatic cancer should be offer...


Treatment

...reatment

First-Line Treatmen...

...OX (leucovorin, fluorouracil, irinotecan, and ox...

...s NAB-paclitaxel is recommended for patients w...

...mcitabine alone is recommended for patients who...

...ts with an ECOG PS 3 or with poorly controlled...


...t Options Following First-Line Therapy...

...ith tumors harboring NTRK fusions, treatment with...

...ckpoint inhibitor pembrolizumab is recommended...

...o have a germline BRCA1 or BRCA2 mut...

...s NAB-paclitaxel may be offered as second-line t...

...s nanoliposomal irinotecan, or fluor...

...il plus oxaliplatin may be considered as second-li...

...citabine or fluorouracil can be considered as seco...

...vailable to recommend third-line (or greater) the...


...lliative Care...

...with metastatic pancreatic cancer sh...


...tment of Pain and Sympt...

...h metastatic pancreatic cancer should be offe...


Follow-Up

...llow-U...

...w-up/Surveillanc...

...on active cancer-directed therapy o...

No data exist on the duration of canc...